Earlier this month, we spent the afternoon playing yard games and enjoying the scenic views of Boston as part of our annual summer outing! Learn more about Servier’s commitment to fostering a unique company culture: https://ow.ly/8L5N50SJm2R
About us
Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients’ lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us
- Website
-
https://www.servier.us/
External link for Servier Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Boston , MA
- Type
- Nonprofit
Locations
-
Primary
200 Pier Four Boulevard
Boston , MA 02210, US
Employees at Servier Pharmaceuticals
Updates
-
We are excited to celebrate two years of our U.S. research center and reflect on the remarkable growth Servier has experienced. We are proud of the achievements of our #biotech hub in Boston and remain dedicated to driving innovation in oncology. Here’s to many more years of breakthroughs and improving the lives of the patients we serve. https://ow.ly/iaCp50SHi7A
-
We’re proud to announce that we are a finalist for the Biotech Week Boston Awards for the second consecutive year, this year in the Clinical Advance of the Year category. We’re honored to be recognized and look forward to the event in September! https://ow.ly/CWjQ50SEspG
-
We’re proud to celebrate #BastilleDay and honor Servier’s French heritage. Happy French-American Heritage Month! Discover more about our company’s history: https://ow.ly/nGhw50SAHIP
-
Facing a glioma diagnosis can be challenging. Discover essential tools and resources at My Glioma Guide to support you through this journey: https://ow.ly/k53E50SyO1N
-
Our team hosted an insightful moderated discussion on the importance of sustaining Diversity, Equity, and Inclusion (DEI) initiatives in the workplace, within the life sciences community, with patients, and with partners. Our conversation shed light on what DEI and health equity means for different employee and patient populations and how we can better support them. Thank you to our speakers! Scout: Executive Director of National LGBTQI+ Cancer Network Tom Browne: Head of DEI Initiatives and Programming for MassBio Fernando Adriano: Senior Oncology Consultant for Servier NE Region and Registered Nurse
-
Phase 1 data for our treatment in patients in China with IDH-mutant acute myeloid leukemia (AML) was recently published in Blood Science, the journal of the American Society of Hematology. These results demonstrated consistent safety and clinical benefits in this challenging and hard-to-treat cancer. Read more: https://lnkd.in/g9RjGXr5
-
The signs and symptoms of glioma are not the same for everyone, varying based on the size and location of the tumor. Learn more about the common symptoms and manifestations of glioma here: https://lnkd.in/gWZ8P7bM
-
We are excited to announce that POLARIS, our innovative project to enhance communication for acute lymphoblastic leukaemia (ALL) treatment, has been named a finalist for the Langland Award for Excellence in Healthcare Partnership! POLARIS was a collaborative development between Servier, SIOP Europe, the European Society for Paediatric Oncology (SIOPE), CCI Europe, Syneos Health France and the Velella Group, that provides clear, accessible treatment roadmaps and personalized web-based support, helping families track treatments in real-time and in their native languages. Thank you to our partners and to the Communique Awards for this recognition! We remain committed to empowering families and improving the ALL treatment journey. https://lnkd.in/eBXu_t6f #HealthcareExcellence #AwardWinning #HealthcarePartnership #PatientCentric #InnovationInHealthcare #Servier #SyneosHealth
Finalists 2024
https://communiqueawards.com